

[Asparaginase](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01XX02](#)

EMLc

Indication

Lymphoid leukaemia, not elsewhere classified ICD11 code: [2B33.3](#)

Medicine type

Biological agent

List type

Core

Formulations

Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

EML status history

First added in 2015 ([TRS 994](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Biological

Wikipedia

[Asparaginase](#)

[DrugBank](#)

[Asparaginase](#)

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for asparaginase on the complementary list of the EML and EMLc for use in treatment protocols for acute lymphoblastic leukaemia (ALL) was recommended. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for ALL is attached.